Interpreting results from oncology clinical trials: A comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1353-1360

  Dranitsaris, George ^a   Hatzimichael, Eleftheria ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast; Denosumab; Number needed to treat; Prostate; Zoledronic acid

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

BONE DISEASE; BREAST CANCER; DRUG WITHDRAWAL; HEALTH CARE CONCEPTS; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MULTIPLE MYELOMA; NEPHROTOXICITY; NUMBER NEEDED TO TREAT; ONCOLOGY; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMIDAZOLES; MALE; NEOPLASMS; NUMBERS NEEDED TO TREAT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863984215     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1461-4     Document Type: Review

References (28)

1. Carter JA, Snedecor SJ, Kaura S et al (2011) Cost-effectiveness of zoledronic acid versus denosumab in prevention of skeletal-related events in metastatic breast cancer. J Clin Oncol 29, suppl; abstr 9025
2. Clark JC, Dass CR, Choong PF (2008) Current and future treatments of bone metastases. Expert Opin Emerg Drugs 13:609-27
3. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14-27
4. Delea T, McKiernan J, Brandman J et al (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4:341-7
5. Dranitsaris G, Truter I, Lubbe MS et al (2011) Advances in cancer therapeutics and patient access to new drugs. PharmacoEconomics 29:213-24
6. FDA Approval for Denosumab. November 18, 2010. Available at http://www.cancer.gov/cancertopics/druginfo/fda-denosumab.Accessed 15 August 2011
7. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-22
8. Good PI, Hardin JW (2006) Common errors in statistics. Wiley, New Jersey, pp 80-84
9. Guyatt GH, Sackett DL, Cook DJ (1993) User's guides to the medical literature; how to use an article about therapy or prevention A. JAMA 270:2598-2601
10. Guyatt GH, Sackett DL, Cook DJ (1994) User's guides to the medical literature; how to use an article about therapy or prevention B. JAMA 271:59-63
11. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-32
12. Henry J, McQuary DM, Moore AR (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126:712-20
13. Lage MJ, Barber BL, Harrison DJ, Jun S (2008) The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care 14:317-22
14. Lipton A, Jun S (2008) RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2:197-203
15. Martin M, Steger G, von Moos R, et al (2011) Benefit of denosumab therapy in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis on behalf of the 136 study investigators [abstract]. Presented at the 12th St. Gallen International Breast Cancer Conference; 16-19 March; St. Gallen, Switzerland. Abstract P347
16. Miller K, Fizazi K, Smith M, et al. (2011) Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (NNT) analysis [abstract]. Presented at the AUA Annual Meeting; 14-19 May; Washington, DC. Abstract 648
17. Nørgaard M, Jensen AO, Jacobsen JB et al (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162-7
18. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474. doi:10.1002/14651858.CD003474.pub2
19. Richardson GE, Ciuleanu TE, Costa L et al (2011) Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: a number needed to treat (NNT) analysis. J Clin Oncol 29, suppl; abstr 9115
20. Roland M, Torgerson D (1998) Understanding controlled trials: what outcomes should be measured? BMJ 317:1075
21. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655-1664
22. Rosen LS, Gordon DH, Dugan W et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43
23. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
24. Santini D, Fratto ME, Vincenzi B et al (2009) Denosumab: the era of targeted therapies in bone metastatic diseases. Curr Cancer Drug Targets 9:834-842
25. Schechtman E (2002) Odds ratio, relative risk, absolute risk reduction, and the number needed to treat-which of these should we use? Value Health 5:431-6
26. Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-9
27. West H (2011) Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol 29:1095-8
28. Xie J, Namjoshi M, Wu EQ et al (2011) Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 17:621-43